Ergoline Compounds Modulating Serotonin Receptors for Neural Plasticity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psychedelic compounds with hallucinogenic properties, such as LSD, have limitations in clinical use due to their hallucinogenic and dissociative effects, which hinder their application in treating neurological diseases characterized by altered synaptic connectivity and plasticity.
Innovation Solution
Development of non-hallucinogenic ergoline-derived compounds that promote neuronal growth and plasticity by modulating serotonin 5-HT2A and 5-HT2C receptors, with improved physicochemical properties and reduced hallucinogenic potential, allowing for therapeutic efficacy without dissociative side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hallucinogenic compounds like LSD are used to promote neural plasticity, then therapeutic efficacy is improved, but hallucinogenic side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of ergoline compounds through systematic variation of substituents at different positions on the molecule. This includes changing R groups, ring structures, and functional groups to tune the balance between 5-HT2A receptor affinity (therapeutic effect) and hallucinogenic activity, thereby achieving compounds with maintained efficacy but reduced side effects
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and substituents at particular positions on the ergoline scaffold. Different regions of the molecule are optimized independently - for example, modifying the indole ring, the ergoline ring system, or side chain groups - to achieve localized effects on receptor binding properties that collectively reduce hallucinogenic activity while preserving plasticity-promoting effects
2Reliability
If ergoline scaffold compounds are used for neural plasticity, then antidepressant effects are achieved, but synthesis complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex ergoline molecule into modular components that can be synthesized separately and then assembled. The indole ring system, the ergoline core, and side chain substituents are developed as independent building blocks with standardized connection points, enabling systematic assembly of diverse analogs through combinatorial chemistry approaches
Solution Approach 2:
The patent applies universality by developing a core ergoline scaffold with universal binding properties that can accommodate various substituent patterns. This modular platform allows a single core structure to serve multiple therapeutic purposes by simply changing peripheral groups, thereby simplifying the overall synthesis strategy while maintaining diverse biological activities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively increase neural plasticity and dendritic spine density, offering therapeutic benefits for neurological diseases while minimizing hallucinogenic effects, thus providing a safer and more effective treatment option.
Implementation Method 1
Psychoplastogens promote neuronal growth and improve neuronal architecture through mechanisms involving the activation of the serotonin 5-HT2A and 5-HT2C receptors
Data Source
AI summary
Provided herein are ergoline-derived heterocyclic compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.